Molecular Weight(MW): 113.61
Cysteamine is an agent for the treatment of nephropathic cystinosis and an antioxidant.
Purity & Quality Control
|Description||Cysteamine is an agent for the treatment of nephropathic cystinosis and an antioxidant.|
Cysteamine has been shown to increase intracellular glutathione levels in cystinotic cells, thus restoring the altered redox state of the cells. Also increased rates of apoptosis in cystinotic cells, which are thought to be the result of increased caspase 3 and protein kinase Cε activity, is counteracted by Cysteamine administration. Cysteamine has antioxidant properties as a result of increasing glutathione production. Cysteamine is an excellent scavenger of OH and HOCl; it also reacts with H2O2. Cysteamine increases the production of several heat shock proteins (HSP), including the murine Hsp40. Cysteamine exerts a dose-dependent effect on the doxorubicin-induced death of cancer cells, measured in both HeLa cells and B16 cells, whereas Cysteamine treatment alone had no influence on cell survival. In addition, in a doxorubicin-resistant breast cancer cell line, the addition of Cysteamine to doxorubicin results in a dramatic increase in cell death.  Cysteamine (100 μM) significantly is able to increase the intracellular GSH levels and the percentage of embryos that developed to the blastocyst stage of culture matured oocytes. 
|In vivo||Cysteamine is introduced as a treatment for cystinosis by depleting lysosomal cystine. Cystamine can inhibit transglutaminase activity by binding to the cysteine in its active center. Cysteamine increases brain levels of brain-derived neurotrophic factor (BDNF), which is caused by the increased expression of the heat shock DNAJ-containing protein 1 (HSJ1). Cysteamine inhibits the formation of gastric and mammary tumors that are induced chemically or after irradiation, respectively. The administration of Cysteamine is also able to inhibit the metastasis of pancreatic cancer in a mouse model by decreasing the expression and activity of metalloproteinases. |
|In vitro||DMSO||23 mg/mL (202.44 mM)|
|Water||23 mg/mL (202.44 mM)|
|Ethanol||23 mg/mL (202.44 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03000348||Completed||Drug: Cysteamine|Drug: Placebo Oral Capsule||Cystic Fibrosis||NovaBiotics Ltd.|Agility Clinical Inc.|PSR Group B.V.||December 2016||Phase 2|
|NCT02212431||Completed||Drug: Cysteamine||Cystic Fibrosis||University of Aberdeen|Cystic Fibrosis Trust|NHS Grampian|University of Huddersfield||August 2014||Phase 1|Phase 2|
|NCT01733316||Completed||Drug: RP103|Drug: Cystagon®||Cystinosis||Horizon Pharma USA Inc.||January 31 2013||Phase 3|
|NCT01744782||Completed||Drug: RP103||Cystinosis||Horizon Pharma USA Inc.||December 20 2012||Phase 3|
|NCT02012114||Unknown status||Other: Cysteamine bitartrate||Cystinosis||Hospices Civils de Lyon||December 2011||Not Applicable|
|NCT01432561||Completed||Drug: Cysteamine bitartrate||Cystinosis|Nephropathic Cystinosis||University of California San Diego|Raptor Pharmaceuticals Corp.||September 2011||Not Applicable|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.